Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

IR Thematic Conference Call on Alirocumab

September 02, 2014

Sanofi and Regeneron hosted an IR Thematic Conference Call for the financial community focusing on alirocumab during the European Society of Cardiology Congress in Barcelona.

Alirocumab (SAR236553/ REGN727) is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) for the reduction of LDL-cholesterol. Alirocumab is currently being evaluated in a large Phase 3 program in patients with hypercholesterolemia.
 

 

 

 

 

Right area:

Stock Market

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

SANOFI IR is available on iPhone, iPad, Apple Watch and Android!
NEW - Section dedicated to Individual Shareholders

 

Your services

 

© Sanofi 2004-2017 - All rights reserved - Update: November 29, 2016

  • Site complies with W3C WCAG 2.0 (new window, in english)